Letter to the editorSeason of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma
References (10)
- et al.
Rhinovirus illnesses during infancy predict subsequent childhood wheezing
J Allergy Clin Immunol
(2005) - et al.
Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing
J Allergy Clin Immunol
(2004) - et al.
Risk of primary infection and reinfection with respiratory syncytial virus
Am J Dis Child
(1986) - et al.
The Tucson Children's Respiratory Study. II. Lower respiratory tract illness in the first year of life
Am J Epidemiol
(1989) The Jeremiah Metzger lecture. Climatology and the common cold
Trans Am Clin Climatol Assoc
(1985)
Cited by (67)
Azithromycin therapy in infants hospitalized for respiratory syncytial virus bronchiolitis: Airway matrix metalloproteinase-9 levels and subsequent recurrent wheeze
2024, Annals of Allergy, Asthma and ImmunologyNasopharyngeal airway dual-transcriptome of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study
2022, Journal of Allergy and Clinical ImmunologyThe impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?
2020, Paediatric Respiratory ReviewsLessons learned from birth cohort studies conducted in diverse environments
2017, Journal of Allergy and Clinical ImmunologyRhinovirus during childhood: Asthma at adolescence? The chicken or the egg causality dilemma
2016, Archives de PediatrieFall-winter: Viral infection and allergy
2016, Revue Francaise d'Allergologie
Supported by National Institutes of Health (NIH) grant U01 HL 072471 (T.V.H.), the Thrasher Research Fund (T.V.H. and P.W./T.V.H.), NIH grant KO1 AI070808 (K.N.C.), NIH grant K24 AI 077930 (T.V.H.), NIH grant F32 HL 086048 (P.W./T.V.H.), NIH grant RO1 AI 50884 (T.V.H.), and the Parker B. Francis Fellowship in Pulmonary Research (K.N.C.).
Disclosure of potential conflict of interest: K. N. Carroll has received research support from the National Institutes of Health and the Parker B. Francis Foundation. P. Wu has received research support from the National Institutes of Health and the Thrasher Research Fund. M. R. Griffin has received research support from MedImmune, Pfizer, the Centers for Disease Control and Protection, and the Agency for Healthcare Research and Quality. W. D. Dupont has received research support from the National Institutes of Health/National Cancer Institute and the National Institutes of Health/National Institute of Allergy and Infection Diseases. T. V. Hartert has served as a consultant/speaker for Merck, has received extramural grants from the National Institutes of Health and the Thrasher Research Fund, and is a committee member of the American Thoracic Society. The rest of the authors have declared that they have no conflict of interest.
- ∗
These authors contributed equally to this work.